Jubilant Biosys expands drug discovery alliance with Janssen

Company will carry out research services and deliver preclinical candidates to Janssen for potential development and commercialisation

Jubilant Biosys, an arm of Jubilant Life Sciences, today announced expansion of its drug discovery alliance with Janssen Pharmaceutica NV into multiple therapeutic areas.

The alliance which was forged initially in the year 2011 to deliver preclinical candidates to Janssen, has been expanded to leverage Jubilant's drug discovery capabilities on selected drug discovery targets to advance programmes in multiple disease areas, the company said in a statement.

"Most of the research will be undertaken at Jubilant Biosys, India and some parts at Jubilant Discovery Centre, USA," it added.

Commenting on the development, Jubilant Biosys President (Global Drug Discovery Services) Subir K Basak said: "Over the past several years, we have been strengthening our disease franchises from a scientific perspective, and this collaboration serves as a validation of those efforts. We look forward to a long and mutually beneficial partnership."

Jubilant Biosys will carry out research services and deliver preclinical candidates to Janssen for potential development and commercialisation.

"In addition to research funding, Jubilant will also receive milestones and royalties should Janssen successfully progress the assets into clinical development and commercialisation," the company said.

Jubilant provides comprehensive drug discovery solutions from target discovery to IND (investigational new drug) in partnership with leading healthcare companies worldwide.

Janssen Pharmaceutica, Belgium is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.